Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLP mKRASvax, Balstilimab, and Botensilimab for Stage IV MMR-p Colorectal and Pancreatic Cancer
NCT06411691Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mKRASvax, balstilimab and botensilimab in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Progression-Free Survival at 4 months, Objective Response Rate at 3 years and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
mKRASvaxbalstilimabbotensilimab
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06411691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411691.